Indication

Hypereosinophilic syndrome

Hypereosinophilic syndrome comprises a heterogeneous group of rare disorders characterized by marked, sustained overproduction of eosinophils in peripheral blood or tissues without identifiable secondary causes. Read more about Hypereosinophilic syndrome

31 drugs 29 manufacturers

Advertisement

Drugs that treat it

Common Hypereosinophilic syndrome therapies.

Showing 1–9 of 31 drugs

GLEEVEC (imatinib mesylate)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Novartis Pharmaceuticals

NUCALA (mepolizumab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 5 ANTAGONIST·HYPEREOSINOPHILIC SYNDROME·+4
GSK

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
SUN PHARMA GLOB

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
APOTEX CORP

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
TEVA USA

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Mylan Pharmaceuticals

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
MYLAN INSTITUTI

FASENRA (benralizumab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 5 ANTAGONIST·HYPEREOSINOPHILIC SYNDROME·+2
AstraZeneca Pharmaceuticals

IMATINIB MESYLATE

PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
NORTHSTAR RX LL
Filter & compare in the drug finder →Opens the drug finder with Hypereosinophilic syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hypereosinophilic syndrome.

Hypereosinophilic syndrome comprises a heterogeneous group of rare disorders characterized by marked, sustained overproduction of eosinophils in peripheral blood or tissues without identifiable secondary causes.

The condition occurs predominantly in adults, though it can manifest at any age.

Pathophysiologically, sustained hyperactivation and degranulation of eosinophils lead to cytotoxicity, local inflammation, and progressive tissue remodeling.

Clinical manifestations vary widely according to the pattern of tissue infiltration, frequently producing multiorgan dysfunction or damage across the dermatologic, cardiac, pulmonary, gastrointestinal, and central or peripheral nervous systems.

Personalize your experience

Follow Hypereosinophilic syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it